130 related articles for article (PubMed ID: 32717219)
1. The induction of AMPK-dependent autophagy leads to P53 degradation and affects cell growth and migration in kidney cancer cells.
Patergnani S; Guzzo S; Mangolini A; dell'Atti L; Pinton P; Aguiari G
Exp Cell Res; 2020 Oct; 395(1):112190. PubMed ID: 32717219
[TBL] [Abstract][Full Text] [Related]
2. Role of AMPK/mTOR-independent autophagy in clear cell renal cell carcinoma.
Radovanovic M; Vidicevic S; Tasic J; Tomonjic N; Stanojevic Z; Nikic P; Vuksanovic A; Dzamic Z; Bumbasirevic U; Isakovic A; Trajkovic V
J Investig Med; 2020 Dec; 68(8):1386-1393. PubMed ID: 33087428
[TBL] [Abstract][Full Text] [Related]
3. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
Taniguchi H; Ito S; Ueda T; Morioka Y; Kayukawa N; Ueno A; Nakagawa H; Fujihara A; Ushijima S; Kanazawa M; Hongo F; Ukimura O
Biochem Biophys Res Commun; 2017 Apr; 485(2):267-271. PubMed ID: 28235487
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of miR-34a-5p can rescue disruption of the p53-DAPK axis to suppress progression of clear cell renal cell carcinoma.
Jing ZF; Bi JB; Li Z; Liu X; Li J; Zhu Y; Zhang XT; Zhang Z; Li Z; Kong CZ
Mol Oncol; 2019 Oct; 13(10):2079-2097. PubMed ID: 31294899
[TBL] [Abstract][Full Text] [Related]
5. PLCL1 suppresses tumour progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma.
Pan Z; Huang J; Song H; Xiao Y; Liu T; Zeng Y; Zhu H; Yang K
Aging (Albany NY); 2023 Oct; 15(19):10407-10427. PubMed ID: 37801481
[TBL] [Abstract][Full Text] [Related]
6. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
7. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.
Joshi S; Tolkunov D; Aviv H; Hakimi AA; Yao M; Hsieh JJ; Ganesan S; Chan CS; White E
Cell Rep; 2015 Dec; 13(9):1895-908. PubMed ID: 26655904
[TBL] [Abstract][Full Text] [Related]
8. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol-mediated apoptosis in renal cell carcinoma via the p53/AMP‑activated protein kinase/mammalian target of rapamycin autophagy signaling pathway.
Liu Q; Fang Q; Ji S; Han Z; Cheng W; Zhang H
Mol Med Rep; 2018 Jan; 17(1):502-508. PubMed ID: 29115429
[TBL] [Abstract][Full Text] [Related]
10. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.
Kearney AY; Fan YH; Giri U; Saigal B; Gandhi V; Heymach JV; Zurita AJ
PLoS One; 2015; 10(8):e0135962. PubMed ID: 26313261
[TBL] [Abstract][Full Text] [Related]
11. RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.
Yu S; Dai J; Ma M; Xu T; Kong Y; Cui C; Chi Z; Si L; Tang H; Yang L; Sheng X; Guo J
Cell Death Dis; 2019 Mar; 10(4):254. PubMed ID: 30874541
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway.
Su Y; Lu J; Chen X; Liang C; Luo P; Qin C; Zhang J
J Cancer Res Clin Oncol; 2019 Mar; 145(3):573-588. PubMed ID: 30511250
[TBL] [Abstract][Full Text] [Related]
13. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours.
Mastropasqua F; Marzano F; Valletti A; Aiello I; Di Tullio G; Morgano A; Liuni S; Ranieri E; Guerrini L; Gasparre G; Sbisà E; Pesole G; Moschetta A; Caratozzolo MF; Tullo A
Mol Cancer; 2017 Mar; 16(1):67. PubMed ID: 28327152
[TBL] [Abstract][Full Text] [Related]
14. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.
Gurova KV; Hill JE; Razorenova OV; Chumakov PM; Gudkov AV
Cancer Res; 2004 Mar; 64(6):1951-8. PubMed ID: 15026329
[TBL] [Abstract][Full Text] [Related]
15. Expression and Prognostic Significance of
Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwińska-Jewsiewicka A; Wierzbicki PW; Kmieć Z
Anticancer Res; 2017 Jun; 37(6):2927-2937. PubMed ID: 28551630
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-21 expression is a valuable predicator of advanced clinicopathological features and poor prognosis in patients with renal cell carcinoma through the p53/p21‑cyclin E2‑Bax/caspase-3 signaling pathway.
Liu Z; Lu Y; Xiao Y; Lu Y
Oncol Rep; 2017 Mar; 37(3):1437-1444. PubMed ID: 28184919
[TBL] [Abstract][Full Text] [Related]
17. B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma.
Nientiedt M; Müller K; Nitschke K; Erben P; Steidler A; Porubsky S; Popovic ZV; Waldbillig F; Mühlbauer J; Kriegmair MC
J Cancer Res Clin Oncol; 2021 Jan; 147(1):129-138. PubMed ID: 32951068
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of growth 4 inhibits cell proliferation, migration, and induces apoptosis of renal cell carcinoma cells.
Sun J; Xie L; Lv J; Zhang W; Lv J; Liang Y; Geng Y; Li X
J Cell Biochem; 2019 Apr; 120(4):6709-6717. PubMed ID: 30390334
[TBL] [Abstract][Full Text] [Related]
19. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.
Macher-Goeppinger S; Keith M; Tagscherer KE; Singer S; Winkler J; Hofmann TG; Pahernik S; Duensing S; Hohenfellner M; Kopitz J; Schirmacher P; Roth W
J Pathol; 2015 Dec; 237(4):460-71. PubMed ID: 26178300
[TBL] [Abstract][Full Text] [Related]
20. Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.
Chen J; Zhu H; Zhang Y; Cui MH; Han LY; Jia ZH; Wang L; Teng H; Miao LN
Mol Med Rep; 2015 Aug; 12(2):2622-8. PubMed ID: 25954860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
